Protalix BioTherapeutics Shares Financial and Business Progress for Fiscal Year 2025 Protalix BioTherapeutics recently reported its fiscal year 2025 results and discussed significant advancements, including regulatory approvals and pipeline developments.

Protalix BioTherapeutics Shares Financial and Business Progress for Fiscal Year 2025 #Israel #Protalix_BioTherapeutics #Elfabrio #Carmiel #PRX-115

Protalix BioTherapeutics Unveils 2026 Strategy and Pipeline Developments for Rare Diseases Protalix BioTherapeutics shares updates on its strategic initiatives for 2026, focusing on innovative therapies for rare diseases, including clinical developments and commercial execution.

Protalix BioTherapeutics Unveils 2026 Strategy and Pipeline Developments for Rare Diseases #Israel #Protalix_BioTherapeutics #Carmiel #PRX-115 #PRX-119

Protalix BioTherapeutics Reports Third Quarter 2025 Performance and Future Plans Protalix BioTherapeutics announces its Q3 2025 performance, highlighting revenue growth and future clinical trials for innovative treatments in biotechnology.

Protalix BioTherapeutics Reports Third Quarter 2025 Performance and Future Plans #Israel #Elfabrio #Carmiel #PRX-115 #Protalix

Protalix BioTherapeutics Announces Significant Growth in Q2 2025 Financial Results Protalix BioTherapeutics reports substantial revenue growth for Q2 2025, driven by increased sales of Elfabrio. The company highlights expansion plans and leadership changes.

Protalix BioTherapeutics Announces Significant Growth in Q2 2025 Financial Results #Israel #Elfabrio #Carmiel #PRX-115 #Protalix

Protalix BioTherapeutics Welcomes Gilad Mamlok as New CFO Amid Strategic Growth Plans Protalix BioTherapeutics has appointed Gilad Mamlok as its new CFO, effective August 24, 2025. With over 30 years of experience, he aims to enhance the company's growth strategy.

Protalix BioTherapeutics Welcomes Gilad Mamlok as New CFO Amid Strategic Growth Plans #Israel #CFO #Carmiel #Protalix #Gilad_Mamlok

Protalix BioTherapeutics Joins Russell 3000 and 2000 Indexes, Celebrating Milestone Protalix BioTherapeutics recently achieved a significant milestone by being included in the Russell 3000 and Russell 2000 indexes, enhancing its visibility in the market.

Protalix BioTherapeutics Joins Russell 3000 and 2000 Indexes, Celebrating Milestone #Israel #Protalix_BioTherapeutics #Russell_2000 #Carmiel #Russell_3000

Protalix BioTherapeutics Reveals Promising Q1 2025 Financial Results and Pipeline Advances Protalix BioTherapeutics announced Q1 2025 financial results with significant revenue growth, driven by its pipeline advancements in gout treatment and clinical trials.

Protalix BioTherapeutics Reveals Promising Q1 2025 Financial Results and Pipeline Advances #Israel #Clinical_Trials #Protalix_BioTherapeutics #Carmiel #PRX-115

Protalix BioTherapeutics to Showcase Innovations at iAccess Alpha Conference 2025 Protalix BioTherapeutics will present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025, focusing on innovative biopharmaceutical solutions and investment opportunities.

Protalix BioTherapeutics to Showcase Innovations at iAccess Alpha Conference 2025 #Israel #Carmiel #Protalix #iAccess_Alpha #Conference_2025

Protalix BioTherapeutics Unveils Strong Financial Growth and Ambitious Clinical Developments for FY 2024 Protalix BioTherapeutics has reported impressive revenue growth for fiscal year 2024, alongside promising advancements in clinical trials for gout medications. The company aims to initiate a phase II trial soon.

Protalix BioTherapeutics Unveils Strong Financial Growth and Ambitious Clinical Developments for FY 2024 #Israel #Protalix_BioTherapeutics #Carmiel #PRX-115 #Fabry_disease

Protalix BioTherapeutics 2025 Stockholder Letter Details Achievements and Future Goals Protalix BioTherapeutics details its notable milestones and plans for the future in a letter to stockholders, highlighting innovative therapies and financial discipline.

Protalix BioTherapeutics 2025 Stockholder Letter Details Achievements and Future Goals #Israel #Protalix_BioTherapeutics #Chiesi_Global_Rare_Diseases #Elfabrio #Carmiel